NCT03974360View on ClinicalTrials.gov

Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Post-Traumatic HeadacheMild Traumatic Brain InjuryPost-Concussion Syndrome
Interventions
DRUG

AMG 334

100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)

Trial Locations (1)

2600

Danish Headache Center, Glostrup Municipality

Sponsors

Collaborators (2)

Novartis
Amgen
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

Danish Headache Center

OTHER